Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
LH beats Q4 EPS estimates with 18% growth, but a revenue miss and cautious investor reaction push shares lower in pre-market trading.
| Health Care Providers & Services Industry | Healthcare Sector | Adam H. Schechter CEO | XMEX Exchange | US50540R4092 ISIN |
| US Country | 60,900 Employees | 12 Mar 2026 Last Dividend | 3 Jul 2023 Last Split | 29 Mar 1990 IPO Date |
Laboratory Corporation of America Holdings, widely known as Labcorp, is a pioneering life sciences company that plays a crucial role in the healthcare industry by providing essential information aiding in clear and confident decision-making for doctors, hospitals, pharmaceutical companies, researchers, and patients. With a deep commitment to improving health and improving lives, Labcorp operates through two primary segments: Labcorp Diagnostics, which focuses on a wide array of testing services, and Labcorp Drug Development, dedicated to supporting the pharmaceutical and biotech industries in bringing new drugs and therapies to market. The company's history dates back to 1994, and it has since established its headquarters in Burlington, North Carolina, positioning itself as a leader in medical diagnostics and drug development services. Through its extensive range of services and a global network, Labcorp facilitates better health outcomes for millions of people worldwide.
Labcorp distinguishes itself by offering an extensive portfolio of services that cater to various stakeholders in the healthcare and biomedical sectors. Below are some of the key products and services provided by the company: